Price$20.07-0.77 (-3.67%)
01:45 PM05:15 PM
News · 26 weeks39-87%
2026-04-192026-10-11
Mix1590d
- Insider11(73%)
- Earnings2(13%)
- SEC Filings2(13%)
Latest news
25 items- PRFulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulge
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.58% to 356,543 units (SEC Form 4) (withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 885,952 units (SEC Form 4) to satisfy tax liability4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $32,885 worth of shares (1,673 units at $19.66), decreasing direct ownership by 0.17% to 986,117 units (SEC Form 4) (withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian sold $41,809 worth of shares (2,127 units at $19.66), decreasing direct ownership by 0.59% to 359,924 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 890,344 units (SEC Form 4) (withholding obligation)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 358,630 units (SEC Form 4) to satisfy tax liability4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian sold $23,747 worth of shares (1,193 units at $19.91), decreasing direct ownership by 0.33% to 362,051 units (SEC Form 4) to satisfy withholding tax4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $18,691 worth of shares (939 units at $19.91), decreasing direct ownership by 0.09% to 987,790 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECSEC Form 10-Q filed by Fulgent Genetics Inc.10-Q - Fulgent Genetics, Inc. (0001674930) (Filer)
- SECFulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- PRFulgent Reports Second Quarter 2026 Financial ResultsRevenue of $85.4 million, growing 20.1% sequentially GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% GAAP loss of $29.5 million, or $(1.05) per share; Non-GAAP loss of $16.2 million, or $(0.58) per share Executed on stock repurchase program; purchased approximately 1.5 million shares in the second quarter of 2026 totaling $23.8 million in cash Ended the second quarter of 2026 with $551.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.1 million Revised annual revenue guidance to be
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 2,747 shares, decreasing direct ownership by 0.76% to 359,798 units (SEC Form 4) (withholding obligation)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian covered exercise/tax liability with 4,361 shares, decreasing direct ownership by 1% to 363,244 units (SEC Form 4) to satisfy tax liability4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 0.17% to 988,729 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- PRFulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent
- INSIDERPresident and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 893,293 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- PRFulgent Presents Updated FID-007 Data at ASCO 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study (NCT0633
- INSIDERPresident and COO Xie Jian sold $21,138 worth of shares (1,201 units at $17.60), decreasing direct ownership by 0.32% to 369,751 units (SEC Form 4) (for withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 364,632 units (SEC Form 4) (tax liability)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $16,632 worth of shares (945 units at $17.60), decreasing direct ownership by 0.10% to 992,062 units (SEC Form 4) to cover withholding tax4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
FLGT FAQ
7 questionsWhat does Fulgent Genetics Inc. do?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has...Where does FLGT stock trade?
Fulgent Genetics Inc. (FLGT) is listed on NASDAQ.What sector and industry is FLGT in?
Fulgent Genetics Inc. operates in the Health Care sector, Medical Specialities industry.When did Fulgent Genetics Inc. go public?
Fulgent Genetics Inc. (FLGT) completed its IPO in 2016.What are analysts saying about FLGT?
Fulgent Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $3000.00 price target on 2025-08-05. Recent price targets range from $3000.00 to $4500.00.What companies are similar to FLGT?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare FLGT side-by-side with any of them on Quantisnow.How can I track FLGT on Quantisnow?
Quantisnow aggregates Fulgent Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FLGT to receive live email and push alerts on every new disclosure.